Rapaflo Approved For BPH; Watson Will Stress Unique Selectivity
Even sponsors not aiming for the benign prostatic hyperplasia market should take notice of the Oct. 8 approval of Watson Pharmaceuticals' Rapaflo (silodosin)
Even sponsors not aiming for the benign prostatic hyperplasia market should take notice of the Oct. 8 approval of Watson Pharmaceuticals' Rapaflo (silodosin)